Biomarin Pharm’s Brineura (Cerliponase Alfa) Receives Supplemental Approval In US
BioMarin and England’s cost-effectiveness gatekeeper have been negotiating for a year, but that hasn’t helped the rare-disease specialist secure reimbursement for its Batten disease drug Brineura.
Biomarin Pharm's Biological Cerliponase Alfa Receives Approval in US
Market Place
Share
Cerliponase Alfa News Full Screen View
Share
